Literature DB >> 14742950

Steroid-induced myopathy following a single oral dose of prednisolone.

S Kumar1.   

Abstract

This report describes a case of acute steroid-induced myopathy following a single dose of oral prednisolone. A 55-year-old man presented with an acute exacerbation of chronic obstructive pulmonary disease, which was treated with prednisolone 40 mg daily in addition to bronchodilators. He developed features of myopathy the next day. Serum CPK was moderately elevated and electromyogram was suggestive of primary muscle disease. He was managed conservatively and improved 10 days after stopping prednisolone. Mechanisms of steroid-induced myopathy and relevant literature have been reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14742950

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  6 in total

Review 1.  [Medically induced myopathia].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

2.  Acute myopathy secondary to oral steroid therapy in a 49-year-old man: a case report.

Authors:  Muhammad A Khan; Eric Larson
Journal:  J Med Case Rep       Date:  2011-02-25

3.  [Congenital and endogenous endocrine myopathy].

Authors:  S Wenninger; B Schoser
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

Review 4.  Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence.

Authors:  Ken M Kunisaki; Kathryn L Rice; Dennis E Niewoehner
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  Acute myopathy following intra-muscular injection of compound betamethasone: A case report.

Authors:  Li-Yuan Sun; Xiao-Ling Chu
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

6.  Possible exercised-induced rhabdomyolysis associated with terbinafine.

Authors:  Peter V Bui; Gregory Gafni-Pappas
Journal:  Oxf Med Case Reports       Date:  2019-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.